Drug Information

Drug (ID: DG00347) and It's Reported Resistant Information

• Name: Matrine
• Synonyms: Matrine; 519-02-8; (+)-Matrine; Matrinium; UNII-N390W430AC; CHEBI:6700; Matrene, (+)-; (7aS,13aR,13bR,13cS)-Dodecahydro-1H,5H,10H-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one; N390W430AC; NSC 146051; BRN 0085851; Vegard; alpha-Matrine; cis-Neomatrine; trans-Neomatrine; a-Matrine; Matrine,(S); Matrine ((+)-Matrine); Matridin-15-one (9CI); 5-24-02-00301 (Beilstein Handbook Reference); SCHEMBL177907; CHEMBL204860; DTXSID00274188; HMS3884F13; AMY25701; BCP08193; HY-N0164; ZINC2083329; BDBM50249581; CM0087; MFCD00210527; NSC146051; s2322; AKOS007930266; CCG-208589; CS-1601; KS-5203; NSC-146051; NCGC00346593-01; O723; M2120; N1836; 19M028; (7aS,13aR,13bS,13cS)dodecahydro-1H,5H,10H-dipyrido[2,1-f:3,2,1-ij][1,6]naphthyridin-10-one
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Brain cancer [ICD-11: 2A00]; [1]
• Formula: C15H24N2O
• IsoSMILES: C1C[C@@H]2[C@H]3CCCN4[C@H]3[C@@H](CCC4)CN2C(=O)C1
• InChI: 1S/C15H24N2O/c18-14-7-1-6-13-12-5-3-9-16-8-2-4-11(15(12)16)10-17(13)14/h11-13,15H,1-10H2/t11-,12+,13+,15-/m0/s1
• InChIKey: ZSBXGIUJOOQZMP-JLNYLFASSA-N
• PubChem CID: 91466

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Brain cancer [ICD-11: 2A00]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: hsa_circ_104075 [1]

• Molecule Alteration: Expression; Down-regulation
• Resistant Disease: Glioma [ICD-11: 2A00.1]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell apoptosis; Inhibition; hsa04210
• Cell Pathway Regulation: Cell growth; Activation; hsa05200
• Cell Pathway Regulation: Wnt/Beta-catenin/PI3K/AKT signaling pathway; Inhibition; hsa04310
• In Vitro Model: U251 cells; Brain; Homo sapiens (Human); CVCL_0021
• Experiment for Molecule Alteration: qRT-PCR
• Experiment for Drug Resistance: CCK8 assay; Flow cytometry assay
• Mechanism Description: Matrine inhibits Bcl-9 expression through down-regulating circRNA-104075 expression in U251 cells.

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: B-cell CLL/lymphoma 9 protein (BCL9) [1]

• Molecule Alteration: Expression; Down-regulation
• Resistant Disease: Glioma [ICD-11: 2A00.1]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell apoptosis; Inhibition; hsa04210
• Cell Pathway Regulation: Cell autophagy; Inhibition; hsa04140
• Cell Pathway Regulation: Wnt/Beta-catenin/PI3K/AKT signaling pathway; Inhibition; hsa04310
• In Vitro Model: U251 cells; Brain; Homo sapiens (Human); CVCL_0021
• Experiment for Molecule Alteration: Western blot analysis; RT-qPCR
• Experiment for Drug Resistance: CCK8 assay; Flow cytometry assay
• Mechanism Description: Matrine inhibits Bcl-9 expression through down-regulating circRNA-104075 expression in U251 cells.

ICD-15: Musculoskeletal/connective-tissue diseases

Osteoporosis [ICD-11: FB83]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: TNF superfamily member 11 (TNFSF11) [2]

• Molecule Alteration: Expression; Down-regulation
• Sensitive Disease: Osteoporosis [ICD-11: FB83.1]
• Experimental Note: Identified from the Human Clinical Data
• Cell Pathway Regulation: NF-kappaB signaling pathway; Inhibition; hsa04064
• Cell Pathway Regulation: AKT signaling pathway; Inhibition; hsa04151
• Cell Pathway Regulation: MAPK signaling pathway; Inhibition; hsa04010
• In Vitro Model: RAW264.7 cells; Ascites; Mus musculus (Mouse); CVCL_0493
• In Vivo Model: C57BL/6 mice; Mus musculus
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: TRAP staining assay
• Mechanism Description: The imbalance between the osteogenic effects of osteoblasts and the osteoclasts of osteoclasts is one of the pathogenesis of postmenopausal osteoporosis. Secretion of estrogen causes an increase in the level of proinflammatory cytokines. Inflammation-induced osteoclast hyperactivity plays a crucial role in the imbalance. Matrine can inhibit osteoclastogenesis, inhibit inflammation and alleviate osteoporosis by regulating the NF-kappa-B/AKT/MAPK pathway.

Key Molecule: TNF superfamily member 11 (TNFSF11) [2]

• Molecule Alteration: Expression; Down-regulation
• Sensitive Disease: Osteoporosis [ICD-11: FB83.1]
• Experimental Note: Identified from the Human Clinical Data
• Cell Pathway Regulation: NF-kappaB signaling pathway; Inhibition; hsa04064
• Cell Pathway Regulation: AKT signaling pathway; Inhibition; hsa04151
• Cell Pathway Regulation: MAPK signaling pathway; Inhibition; hsa04010
• In Vitro Model: RAW264.7 cells; Ascites; Mus musculus (Mouse); CVCL_0493
• In Vivo Model: C57BL/6 mice; Mus musculus
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: TRAP staining assay
• Mechanism Description: The imbalance between the osteogenic effects of osteoblasts and the osteoclasts of osteoclasts is one of the pathogenesis of postmenopausal osteoporosis. Secretion of estrogen causes an increase in the level of proinflammatory cytokines. Inflammation-induced osteoclast hyperactivity plays a crucial role in the imbalance. Matrine can inhibit osteoclastogenesis, inhibit inflammation and alleviate osteoporosis by regulating the NF-kappa-B/AKT/MAPK pathway.

References

• Ref 1: Matrine induces apoptosis and autophagy of glioma cell line U251 by regulation of circRNA-104075/BCL-9. Chem Biol Interact. 2019 Aug 1;308:198-205. doi: 10.1016/j.cbi.2019.05.030. Epub 2019 May 18.
• Ref 2: Matrine: A Promising Natural Product With Various Pharmacological Activities .Front Pharmacol. 2020 May 7;11:588. doi: 10.3389/fphar.2020.00588. eCollection 2020. 10.3389/fphar.2020.00588